Abstract 95P
Background
To compare the pathological complete response rates and toxicity in patients receiving long-course neoadjuvant chemoradiotherapy versus total neoadjuvant therapy in locally advanced carcinoma rectum.
Methods
Biopsy-proven newly diagnosed patients of locally advanced rectal adenocarcinoma clinical tumor stage were randomized. Arm A patients received short-course radiotherapy (25 Gy in 5 fractions over seven days) followed by six cycles of CAPEOX chemotherapy (Capecitabine 825 mg/m2 orally twice daily D1-D14 and oxaliplatin 130 mg/m2 on day 1) at intervals of 21 days. Arm B patients received concurrent chemoradiation (50.4 Gy in 28 fractions, five fractions in a week with concurrent tablet capecitabine 825 mg/m2 orally twice daily). Total Mesorectal Excision was done in both arms 6 to 8 weeks after completion of neoadjuvant treatment.
Results
60 patients were included in the study, 30 patients in each arm. Both arms were balanced in terms of the age of the patient, sex, stage of the disease, and tumor location. The median interval between randomization and surgery was 32 weeks and 20 weeks in the experimental arm and control arm, respectively. 9 out of 30 (33.3%) patients in the experimental arm and 6 out of 30 (20%) patients in the control arm had Pathological complete responses (p=0.682). At a median follow-up of 12 months, 6 out of 30 patients developed distant metastases in the standard arm as compared to 1 out of 15 patients in the experimental arm. Grade 3 or higher gastrointestinal adverse events were higher in the experimental arm (20%) as compared to (7%) in the standard arm (p-value=0.59). The requirement of colostomy during surgery was 46% in arm A as compared to 55.5% in arm B (p-value=1.0). Table: 95P
MRI response | ARM A | ARM B |
T3-> T1/2 | 33% | 26% |
T4-> T1/2 | 6.6% | - |
T4-> T3 | 26% | 20% |
T3-> T0 | 6.6% | - |
N2-> N0 | 26% | 20% |
N1-> N0 | 33% | 20% |
Pathological response | ARM A | ARM B |
pT0 | 33.3% | 20% |
pT1 | 20% | 20% |
pT2 | 6.6% | 13.3% |
pT3 | 26.6% | 20% |
pN0 | 80% | 53.3% |
pN1 | 13.3% | 40% |
pN2 | 6.6% | 6.6% |
Conclusions
Total neoadjuvant therapy in locally advanced carcinoma rectum had a higher complete pathological response than the standard arm. The survival analysis of the trial is awaited.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
All India Institute of Medical Sciences, Intramural Funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
73TiP - Global phase III studies evaluating vepdegestrant in estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: VERITAC-2 and VERITAC-3
Presenter: Hiroji Iwata
Session: Poster Display
Resources:
Abstract
78P - First-in-human phase I study of TT-00434, an orally available FGFR (1-3) inhibitor in patients with advanced solid tumors
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
79P - Accelerated identification of recurrent neoantigens for the development of off-the-shelf cancer vaccines
Presenter: Le Son Tran
Session: Poster Display
Resources:
Abstract
80P - Safety, preliminary efficacy, and pharmacokinetics of HLX26 plus serplulimab in advanced solid tumours: An open-label, dose-escalation phase I study
Presenter: Yanmin Wu
Session: Poster Display
Resources:
Abstract
81P - A first-in-human, multiple dose and dose escalation phase I study to investigate the safety, tolerability and antitumor activity of SmarT cells plus PD-1 blocking antibodies in patients with far advanced/metastatic solid tumors
Presenter: Qin Liu
Session: Poster Display
Resources:
Abstract
82P - NEXUS: A phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies
Presenter: Gloria Chan
Session: Poster Display
Resources:
Abstract
83P - The updated report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/RA payloads, in patients with advanced solid tumors
Presenter: Yinan Shen
Session: Poster Display
Resources:
Abstract
84P - T cell receptor repertoire profiles of tumor -infiltrating lymphocytes improves neoantigen prioritization for personalized cancer immunotherapy
Presenter: Tran Nguyen
Session: Poster Display
Resources:
Abstract
85P - Oligometastatic solid tumors: Disease characteristics and role of local therapies
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
86P - Efficacy and safety of HLX07 monotherapy in advanced cutaneous squamous cell carcinoma: An open-label, multicentre phase II study
Presenter: Changxing Li
Session: Poster Display
Resources:
Abstract